{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 39,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "unfair_advantage",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/3",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.55,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c3cc766-299d-479e-82a6-ded427222d32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.12,
        "y": 0.75
      },
      "kind": "list",
      "text": "Well-tolerated to date and no anticipated drug-drug interactions facilitate combination studies (unlike small molecules); serum biomarker may accelerate development and identify patients with best chance of response",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18d28f5c-812f-447d-ade4-55b20e861edd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.12,
        "y": 0.35
      },
      "kind": "list",
      "text": "Wealth of preclinical studies demonstrate ability to combine with common standards of care to allow access to a large total accessible market",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76bdb1c5-af57-43af-a33a-f0f0392a6854",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.6,
        "y": 0.45
      },
      "kind": "list",
      "text": "Currently in P1b/2 ccRCC; agreed registrational study with the FDA incorporates interim analysis for accelerated approval potential",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e15ea49-f7b5-4e3b-965b-1596d3c0a2d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.6,
        "y": 0.7
      },
      "kind": "list",
      "text": "Currently in P1b Pancreatic Adenocarcinoma Cancer (PDAC) study; pk/pd analysis suggests higher doses should be tested",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a768277-0a57-4679-b8f6-a3a3e1f536d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.12,
        "y": 0.15
      },
      "kind": "list",
      "text": "GAS6/AXL signaling drives metastasis and drug-resistance. ARAV is the only company targeting GAS6.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94428262-e993-406c-ae0f-a3c88b7e1d71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.12,
        "y": 0.55
      },
      "kind": "list",
      "text": "Robust chemistry manufacturing control with high yield and purity; dovetails with clinical to allow for BLA end of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e380cbf-3109-4df6-a6a2-61ffa7436166",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.6,
        "y": 0.15
      },
      "kind": "list",
      "text": "Fast-track designation granted by the FDA for platinum-resistant ovarian cancer; currently in registrational Phase 3 trial with topline data due middle 2023 and potential BLA end 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae74d3a4-ac23-4f8d-b680-b43988da08e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Batiraxcept: A Novel Late-Stage Clinical Program Differentiated from Other Cancer Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "622b8e58-960b-406a-89c1-6a4bcdab28b9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}